Among adults aged 60 years and older, the societal cost per QALY saved was $196,842 for GSK’s Arexvy and $178,557 for Pfizer’s Abrysvo. 1 For adults aged 65 years and older, the cost was $ ...

Steve Debenport Getty Images The CDC said there are currently three RSV vaccines available for adults 60 and older: GSK’s Arexvy, Moderna’s mResvia and Pfizer’s Abrysvo. The CDC advises that ...

The CDC recommends an RSV vaccine—GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo—for all people ages 75 years and older. Adults ages 60–74 who are at an increased risk of RSV ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

Vaccinations have become a traditional part of flu season with the influenza vaccine revised most years to protect from new strains of the illness. But this year’s season could have some of us ...

Moderna's decision to cut R&D by $1.1 billion signals reduced confidence in its Covid business and/or its pipeline. The company's Covid vaccine revenue is declining, and concerns about mRNA ...

Fact checked by Nick BlackmerFact checked by Nick Blackmer Vaccines for the fall and winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines for most people ...

mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding differences in study design – and will be weighed up against the ...